AP2744A - Phenanthrenone compounds, compositions and methods - Google Patents

Phenanthrenone compounds, compositions and methods

Info

Publication number
AP2744A
AP2744A AP2011005562A AP2011005562A AP2744A AP 2744 A AP2744 A AP 2744A AP 2011005562 A AP2011005562 A AP 2011005562A AP 2011005562 A AP2011005562 A AP 2011005562A AP 2744 A AP2744 A AP 2744A
Authority
AP
ARIPO
Prior art keywords
compositions
methods
phenanthrenone
compounds
phenanthrenone compounds
Prior art date
Application number
AP2011005562A
Other languages
English (en)
Other versions
AP2011005562A0 (en
Inventor
Paul Vincent Rucker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2011005562A0 publication Critical patent/AP2011005562A0/xx
Application granted granted Critical
Publication of AP2744A publication Critical patent/AP2744A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AP2011005562A 2008-07-28 2009-07-14 Phenanthrenone compounds, compositions and methods AP2744A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8409508P 2008-07-28 2008-07-28
PCT/IB2009/053044 WO2010013158A1 (fr) 2008-07-28 2009-07-14 Composés de phénanthrénone, compositions et procédés

Publications (2)

Publication Number Publication Date
AP2011005562A0 AP2011005562A0 (en) 2011-02-28
AP2744A true AP2744A (en) 2013-09-30

Family

ID=41037773

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005562A AP2744A (en) 2008-07-28 2009-07-14 Phenanthrenone compounds, compositions and methods

Country Status (39)

Country Link
US (2) US8148409B2 (fr)
EP (1) EP2307375B1 (fr)
JP (1) JP4823397B1 (fr)
KR (1) KR101377860B1 (fr)
CN (1) CN102112446B (fr)
AP (1) AP2744A (fr)
AR (1) AR072535A1 (fr)
AU (1) AU2009278029B2 (fr)
BR (1) BRPI0917212A2 (fr)
CA (1) CA2729578C (fr)
CL (1) CL2011000141A1 (fr)
CO (1) CO6290761A2 (fr)
CR (1) CR20110012A (fr)
CU (1) CU23983B1 (fr)
DK (1) DK2307375T3 (fr)
DO (1) DOP2011000029A (fr)
EA (1) EA018024B1 (fr)
EC (1) ECSP11010795A (fr)
ES (1) ES2527137T3 (fr)
GE (1) GEP20125640B (fr)
GT (1) GT201100026A (fr)
HK (1) HK1154245A1 (fr)
HR (1) HRP20150021T1 (fr)
IL (1) IL210492A (fr)
MA (1) MA32512B1 (fr)
MX (1) MX2011001053A (fr)
NI (1) NI201100028A (fr)
NZ (1) NZ590559A (fr)
PE (1) PE20110559A1 (fr)
PL (1) PL2307375T3 (fr)
PT (1) PT2307375E (fr)
RS (1) RS53747B1 (fr)
SI (1) SI2307375T1 (fr)
SV (1) SV2011003821A (fr)
TW (1) TWI374878B (fr)
UA (1) UA99198C2 (fr)
UY (1) UY32011A (fr)
WO (1) WO2010013158A1 (fr)
ZA (1) ZA201101520B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830234A1 (fr) * 2011-03-15 2012-09-20 Abbvie Inc. Modulateurs des recepteurs hormonaux nucleaires
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (fr) 2012-12-21 2014-06-26 Abbvie Inc. Modulateurs hétérocycliques des récepteurs nucléaires aux hormones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005229A1 (fr) * 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2008093227A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes
WO2008093236A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010138B1 (pt) 1999-04-30 2012-12-11 moduladores de receptores de glicocorticóides.
CA2379650C (fr) 1999-07-30 2008-09-02 Eisai Co., Ltd. Procede de preparation de sels d'addition acides inorganiques d'antibiotiques de base et oxalates intermediaires
EP1201649B1 (fr) 2000-10-28 2006-05-31 Pfizer Products Inc. Modulateurs du récepteur corticoide
EP1201660B1 (fr) 2000-10-30 2005-08-31 Pfizer Products Inc. Modulateurs des récepteurs glucocorticoides
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
ATE540041T1 (de) 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
WO2008070149A2 (fr) 2006-12-05 2008-06-12 Neurogesx, Inc. Promédicaments et procédés pour les fabriquer et les utiliser

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005229A1 (fr) * 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2008093227A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes
WO2008093236A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes

Also Published As

Publication number Publication date
CU23983B1 (es) 2014-03-26
US8552035B2 (en) 2013-10-08
EA018024B1 (ru) 2013-04-30
CO6290761A2 (es) 2011-06-20
NZ590559A (en) 2011-09-30
US20120157502A1 (en) 2012-06-21
UA99198C2 (ru) 2012-07-25
DK2307375T3 (en) 2014-12-08
WO2010013158A1 (fr) 2010-02-04
CA2729578A1 (fr) 2010-02-04
GEP20125640B (en) 2012-09-10
SV2011003821A (es) 2011-07-28
US20100069444A1 (en) 2010-03-18
US8148409B2 (en) 2012-04-03
AU2009278029B2 (en) 2012-05-03
EP2307375B1 (fr) 2014-11-19
JP4823397B1 (ja) 2011-11-24
PL2307375T3 (pl) 2015-03-31
HK1154245A1 (en) 2012-04-13
ECSP11010795A (es) 2011-02-28
SI2307375T1 (sl) 2015-02-27
AP2011005562A0 (en) 2011-02-28
BRPI0917212A2 (pt) 2015-11-10
CN102112446B (zh) 2012-10-31
CN102112446A (zh) 2011-06-29
AU2009278029A1 (en) 2010-02-04
RS53747B1 (en) 2015-06-30
UY32011A (es) 2010-02-26
ES2527137T3 (es) 2015-01-21
GT201100026A (es) 2013-12-10
CU20110020A7 (es) 2011-12-28
CR20110012A (es) 2011-02-10
ZA201101520B (en) 2011-10-26
HRP20150021T1 (en) 2015-03-27
IL210492A0 (en) 2011-03-31
PT2307375E (pt) 2015-01-14
EA201100080A1 (ru) 2011-08-30
EP2307375A1 (fr) 2011-04-13
DOP2011000029A (es) 2014-07-31
NI201100028A (es) 2011-08-05
KR20110022091A (ko) 2011-03-04
TW201014823A (en) 2010-04-16
KR101377860B1 (ko) 2014-03-25
JP2011529103A (ja) 2011-12-01
TWI374878B (en) 2012-10-21
PE20110559A1 (es) 2011-08-06
MX2011001053A (es) 2011-04-21
CA2729578C (fr) 2014-05-27
CL2011000141A1 (es) 2011-06-17
MA32512B1 (fr) 2011-07-03
AR072535A1 (es) 2010-09-01
IL210492A (en) 2015-04-30

Similar Documents

Publication Publication Date Title
GB0815022D0 (en) Composition
GB0819633D0 (en) Composition
EP2282735A4 (fr) Composés, compositions et procédés pour préparer ceux-ci
GB0818473D0 (en) Composition
GB0801119D0 (en) Composition
GB0810554D0 (en) Herbicde composition
GB0818472D0 (en) Composition
GB0809808D0 (en) Composition
GB0811743D0 (en) Composition
GB0801401D0 (en) Composition
EP2357204A4 (fr) Composition
GB0810359D0 (en) Composition
GB0817656D0 (en) Composition
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods
GB0812740D0 (en) Composition
GB0806948D0 (en) Composition
GB0818269D0 (en) Composition
GB0818231D0 (en) Composition
GB0813589D0 (en) Composition
GB0809983D0 (en) Composition
GB0821754D0 (en) Composition
GB0804031D0 (en) Composition
GB0820259D0 (en) Composition
GB0818336D0 (en) Composition
GB0814101D0 (en) Composition